Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia 11Lymphoma 8Sezary Syndrome 4Mycosis Fungoides 4Leukemia, Lymphocytic, Chronic, B-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Recurrence 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Large Granular Lymphocytic 2Leukemia, Biphenotypic, Acute 2Immunoblastic Lymphadenopathy 2Burkitt Lymphoma 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mucositis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1

Interventions

Cyclophosphamide 5pegaspargase 4Vincristine 4Methotrexate 4Cytarabine 4Mercaptopurine 3Etoposide 3Doxorubicin 3Dexamethasone 3fludarabine 2Radiotherapy 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Karyotyping 2Injections, Spinal 2Idarubicin 2ruxolitinib 1palbociclib 1nelarabine 1mogamulizumab 1forodesine 1Prednisone 1Prednisolone 1Positron Emission Tomography Computed Tomography 1Panobinostat 1Mitoxantrone 1Melphalan 1Hydrocortisone 1Everolimus 1Daclizumab 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, T-Cell × nelarabine × Clear all
NCT02518750 2019-04-03

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

St. Jude Children's Research Hospital

Phase 2 Terminated
3 enrolled 6 charts
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, T-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡